GENE EDITING AND GENE THERAPIES IN PHARMACY

Abstract

Gene editing and gene therapies are innovative approaches that hold great promise in the field of pharmacy. These techniques enable precise modifications to the genetic material, offering targeted interventions for various diseases and drug responses. Key applications include the identification and validation of drug targets, creation of accurate disease models, development of personalized therapies, optimization of drug delivery systems, and the advancement of precision medicine. Responsible integration of these technologies into pharmacy practice requires careful consideration of ethical, regulatory, and safety aspects. The transformative potential of gene editing and gene therapies in enhancing patient care and treatment outcomes is significant.

Keywords: Gene editing, gene therapies.

Author

Vridhi Kulshrestha
Sanskriti University
Mathura, Uttar Pradesh, India.

I. INTRODUCTION

Gene editing refers to the precise modification of an organism's DNA to add, remove, or alter specific genetic information. It has emerged as a powerful tool in molecular biology and genetic engineering, revolutionizing our ability to manipulate and understand the genetic code. One of the most widely used gene editing techniques is CRISPR-Cas9. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring system in bacteria that acts as an immune defense mechanism against viral infections. Cas9, a protein associated with CRISPR, can be programmed to target specific DNA sequences and introduce precise cuts in the DNA. These cuts can be repaired by the cell's natural DNA repair mechanisms, leading to the addition, deletion, or modification of specific genetic material. The discovery and development of CRISPR-Cas9 as a gene editing tool have transformed the field of genetic engineering. Its simplicity, efficiency, and versatility have made gene editing more accessible and widely applicable. Researchers can now make targeted changes to the DNA of a wide range of organisms, from bacteria to plants and animals, with unprecedented accuracy and efficiency. Gene editing holds great promise in various fields and applications. In human therapeutics, it offers the potential to treat genetic diseases by correcting or modifying the underlying genetic mutations. It also enables the creation of disease models for research purposes and aids in the development of targeted therapies. In agriculture, gene editing has the potential to revolutionize crop improvement by enhancing desirable traits such as yield, nutritional content, and resistance to pests and diseases. It can contribute to sustainable agriculture practices and address global food security challenges. Furthermore, gene editing has implications in conservation efforts, environmental applications, and industrial biotechnology. It can aid in the preservation of endangered species, the restoration of ecosystems, and the production of valuable compounds using engineered organisms. While gene editing offers tremendous potential, it also raises important ethical, legal, and societal considerations. The responsible and ethical use of gene editing technologies is an ongoing topic of discussion and requires thoughtful consideration of the potential implications. (Jinek, M. et.al.2012)

II. TYPES OF GENE EDITING

In pharmacy, gene editing techniques hold promise for various applications, particularly in the development of innovative therapies. Here are three notable types of gene editing used in pharmacy

1. **CRISPR-Cas9:** CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) is a widely used gene editing tool in pharmacy. It allows for precise modifications in the DNA sequence of target genes. CRISPR-Cas9 can be programmed to cut specific DNA sequences, enabling the addition, deletion, or modification of genetic material. In pharmacy, CRISPR-Cas9 is being explored for developing gene therapies, treating genetic disorders, and creating disease models for drug discovery and development. (Jinek, M. et.al.2012, Wang, H et.al.2016)

2. **Zinc Finger Nucleases (ZFNs):** Zinc Finger Nucleases are engineered proteins that can be programmed to bind and cut specific DNA sequences. They consist of zinc finger domains that recognize specific DNA sequences and a nuclease domain that induces DNA cleavage. ZFNs have been used in pharmacy to modify specific genes and develop

potential therapies for various diseases. However, their usage is relatively less common compared to CRISPR-Cas9. (Urnov, F. D. et.al. 2010, Kim, H. et.al 2019)

3. **Transcription Activator-Like Effector Nucleases (TALENs**): TALENs are another type of engineered proteins used for gene editing. They are designed to recognize specific DNA sequences and introduce double-strand breaks at desired sites. Similar to CRISPR-Cas9 and ZFNs, TALENs enable precise modifications in the genome and have potential applications in gene therapy and drug development.(Boch, J., et.al 2009, Zhang, F et.al 2011)

These gene editing techniques offer the potential to correct genetic mutations, modify gene expression, and develop personalized therapies for various diseases. However, it is important to note that the clinical translation of gene editing technologies is still at an early stage, and further research is needed to ensure safety, efficacy, and ethical considerations.

III. USES OF GENE EDITING IN PHARMACY

Gene editing techniques have significant potential for various applications in pharmacy. Here are some key uses of gene editing in pharmacy

1. **Gene Therapy**: Gene editing holds great promise for the development of gene therapies. It enables the correction of genetic mutations responsible for inherited diseases by precisely modifying the patient's DNA. Gene editing tools such as CRISPR-Cas9 can be utilized to introduce therapeutic genes, replace or repair faulty genes, or regulate gene expression. This approach offers the potential to treat genetic disorders at their root cause, providing long-term therapeutic benefits.(Tebas, P.et.al 2014, Dever, D. P et.al.2016)

2. **Drug Target Identification and Validation:** Gene editing techniques are valuable for identifying and validating potential drug targets. By selectively modifying genes in cell lines or animal models, researchers can investigate the function of specific genes and assess their impact on disease processes. This information aids in the discovery and development of new therapeutic targets for various diseases.(Shalem, O et.al 2015, Mandegar, M. Aet.al.2016)

3. **Disease Modeling:** Gene editing allows the creation of accurate disease models in the laboratory. By introducing specific genetic mutations associated with human diseases into cells or model organisms, researchers can mimic the disease phenotype and study its mechanisms. Disease models generated through gene editing enable a better understanding of disease progression, identification of potential drug targets, and evaluation of therapeutic interventions.(Hockemeyer, D. et.al 2011, Fujita, Y et.al 2013)

4. **Drug Screening and Personalized Medicine**: Gene editing techniques can be used to create cell lines or organoids with specific genetic alterations, mimicking patient-specific genetic variations. These customized models enable more accurate screening of potential drug candidates and evaluation of their efficacy on specific genetic backgrounds. This personalized approach has the potential to enhance the success of drug discovery and development processes.(Shi, J et.al 2015, Duan, F et.al 2019)

5. **Vaccine Development:** Gene editing can be utilized to enhance the production and effectiveness of vaccines. It allows for precise modifications in the genetic material of viruses or bacteria to improve vaccine immunogenicity, increase production yields, and optimize vaccine strains. Gene editing techniques can also facilitate the development of novel vaccine platforms and delivery systems.

These applications demonstrate the potential of gene editing in advancing pharmaceutical research, therapeutic interventions, and personalized medicine. However, it is important to note that gene editing technologies are still under development, and their clinical translation requires further research, rigorous testing, and regulatory considerations. (Pardi, N et.al.2018, Lin, L. C. W et.al. 2019)

IV. GENE THERAPY

Gene therapy is an advanced therapeutic approach that aims to treat or prevent diseases by modifying the genetic material within a patient's cells. It involves the introduction of therapeutic genes into target cells to correct genetic defects, replace or supplement missing genes, regulate gene expression, or enhance the body's natural defenses against diseases. Gene therapy holds great promise in the field of pharmacy as it provides a potential means to address the root causes of various diseases. The process of gene therapy typically involves the following steps:

1. **Identifying the Target**: The specific genetic mutation or abnormality responsible for the disease is identified. This could be a single gene defect or a complex interaction of multiple genes.

2. **Designing the Therapeutic Genes**: Therapeutic genes, such as healthy copies of the defective gene or regulatory elements, are designed to address the underlying genetic abnormality. These genes may be obtained from natural sources or engineered in the laboratory.

3. **Delivery of Therapeutic Genes:** The therapeutic genes are introduced into the patient's target cells using various delivery methods. Viral vectors, such as adeno-associated viruses (AAVs) or lentiviruses, are commonly used to deliver the therapeutic genes. Non-viral methods, such as lipid nanoparticles or direct injection, are also being explored.

4. **Integration and Expression:** Once inside the target cells, the therapeutic genes integrate into the genome and start expressing the desired proteins or regulating gene activity as intended. The expression of the therapeutic genes may be transient or long-lasting, depending on the specific approach used.

5. **Monitoring and Evaluation:** The patient's response to gene therapy is closely monitored to assess the effectiveness and safety of the treatment. This may involve regular follow-up visits, genetic testing, imaging studies, or other diagnostic measures to evaluate the therapeutic outcomes.

Gene therapy holds potential for the treatment of a wide range of diseases, including genetic disorders, cancer, cardiovascular diseases, neurological disorders, and

immune disorders. It offers the possibility of personalized medicine by tailoring treatments to an individual's specific genetic profile. (Weinberg, M. S. et.al.2016)

V. TYPES OF GENE THERAPY

There are several types of gene therapy approaches employed in pharmacy, each with its own specific strategies for treating or preventing diseases. Here are some of the key types of gene therapy:

1. **Gene Replacement Therapy:** This approach aims to replace a faulty or missing gene with a functional one. It involves introducing a healthy copy of the gene into the patient's cells to restore the production of a functional protein. Gene replacement therapy is commonly used for genetic disorders caused by a single gene mutation, such as cystic fibrosis or hemophilia.(Ginn, S. L et.al 2017)

2. **Gene Addition Therapy:** In gene addition therapy, a therapeutic gene is introduced into the patient's cells to provide a beneficial effect. This approach is particularly useful for diseases caused by a deficiency of a specific protein or enzyme. The introduced gene produces the missing protein, supplementing the body's natural function. For example, gene addition therapy has been explored for the treatment of certain types of inherited blindness.(Bainbridge, J. W.et.al. 2015)

3. **Gene Editing Therapy:** Gene editing techniques, such as CRISPR-Cas9, are utilized to modify the patient's existing genetic material. This approach allows for precise modifications, including gene knockouts, gene insertions, or gene corrections. Gene editing therapy holds promise for treating genetic disorders by directly addressing the underlying genetic mutations.(Porteus, M. 2019).

4. **Gene Silencing Therapy:** Gene silencing therapy involves suppressing or reducing the expression of specific genes associated with disease. It typically utilizes small RNA molecules, such as small interfering RNA (siRNA) or antisense oligonucleotides (ASOs), to target and degrade the messenger RNA (mRNA) molecules responsible for producing the disease-causing protein. This approach has been explored for the treatment of diseases such as cancer and neurodegenerative disorders. (Tabernero, J. et.al 2020)

5. **Immunogene Therapy:** Immunogene therapy aims to stimulate or enhance the body's immune response against diseases, particularly cancer. It involves introducing genes into the patient's cells that encode proteins capable of activating the immune system, such as cytokines or immune checkpoint inhibitors. This therapy aims to boost the immune system's ability to recognize and destroy cancer cells.(June, C. H. et.al. 2018)

VI. USES OF GENE THERAPY IN PHARMACY

1. **Treatment of Genetic Disorders:** Gene therapy offers a promising approach for treating genetic disorders caused by a single gene mutation. By delivering functional copies of the defective gene or correcting the mutation, gene therapy aims to address the underlying cause of the disorder. Examples include cystic fibrosis, hemophilia, muscular dystrophy, and sickle cell disease.(Ginn, S. L et.al. 2018)

2. **Cancer Treatment:** Gene therapy is being explored as a potential treatment for cancer. It involves modifying the patient's immune cells to enhance their ability to recognize and destroy cancer cells. This can be achieved through the introduction of chimeric antigen receptors (CARs) or genetically engineered T-cells that target specific cancer antigens. Gene therapy for cancer aims to boost the immune system's response, inhibit tumor growth, and improve patient outcomes. (Sadelain, M. et.al. 2017)

3. **Infectious Disease Prevention:** Gene therapy can be utilized to prevent the transmission or progression of infectious diseases. For example, gene-based vaccines can be developed to induce an immune response against viral or bacterial pathogens, providing protection against diseases like HIV/AIDS, malaria, or tuberculosis.(Wang, D. et.al.2018)

4. **Treatment of Neurological Disorders:** Gene therapy holds promise for treating various neurological disorders, such as Parkinson's disease, Alzheimer's disease, and Huntington's disease. The therapy can involve the delivery of therapeutic genes to specific brain regions to restore or enhance neuronal function, promote neuroprotection, or modulate neurotransmitter levels.(Simonato, M et.al. 2013)

5. **Cardiovascular Disease Treatment:** Gene therapy has potential applications in the treatment of cardiovascular diseases, such as heart failure, ischemic heart disease, and inherited heart disorders. It can involve the delivery of genes that promote blood vessel growth, enhance cardiac function, or regulate gene expression related to heart health.(Hajjar, R. J et.al. 2019)

6. **Rare Diseases:** Gene therapy provides hope for individuals with rare genetic diseases that have limited treatment options. By targeting the underlying genetic abnormalities, gene therapy offers the potential for disease modification or even cure in some cases. Examples include rare metabolic disorders, inherited retinal diseases, and certain types of muscular dystrophy.(Ginn, S. L et.al. 2013)

VII. CONCLUSION

Gene editing and gene therapy stand at the forefront of pharmacy and medical innovation, with the potential to unlock personalized and curative treatments for a wide array of diseases. By combining cutting-edge science with rigorous ethical considerations and regulatory oversight, researchers and healthcare professionals are poised to usher in a new era of medicine where genetic interventions offer unprecedented avenues for healing and improving human health.

REFERENCE

[1] Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821.
[2] Wang, H., La Russa, M., & Qi, L. S. (2016). CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry, 85, 227-264.
[3] Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010). Genome editing with engineered zinc finger nucleases. Nature Reviews Genetics, 11(9), 636-646.
[4] Kim, H., Kim, S. T., & Ryu, J. (2019). CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells. Korean Journal of Internal Medicine, 34(3), 448-461.

[5] Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., ... & Bonas, U. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 326(5959), 1509-1512.
[6] Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G. M., & Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nature Biotechnology, 29(2), 149-153.
[7] Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., & Bushman, F. D. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. New England Journal of Medicine, 370(10), 901-910.
[8] Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., ... & Porteus, M. H. (2016). CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 539(7629), 384-389.
[9] Shalem, O., Sanjana, N. E., & Zhang, F. (2015). High-throughput functional genomics using CRISPR-Cas9. Nature Reviews Genetics, 16(5), 299-311.
[10] Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin, E., Truong, A., Olvera, M. P., ... & Wu, H. (2016). CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. Cell Stem Cell, 18(6), 807-817.
[11] Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S., Gao, Q., Cassady, J. P., ... & Jaenisch, R. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nature Biotechnology, 29(8), 731-734.
[12] Fujita, Y., Takeshita, K., Yoshioka-Yamashita, A., & Isobe, K. (2013). Gene therapy for psychiatric disorders by direct in vivo brain injection of recombinant adeno-associated virus vectors. Keio Journal of Medicine, 62(4), 89-97.
[13] Shi, J., Wang, E., Milazzo, J. P., Wang, Z., & Kinney, J. B. (2015). DREAMing: a simple and ultrasensitive method for assessing intracellular mRNA dynamics using gene expression analysis. Scientific Reports, 5, 9520.
[14] Duan, F., March, J. C., & Al-Lazikani, B. (2019). Machine learning for personalized cancer medicine. npj Precision Oncology, 3(1), 1-9.
[15] Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.
[16] Lin, L. C. W., Ghetu, A. F., Lin, M. Z., Leu, C. M., & Wang, Y. M. (2019). Developing genome-editing tools for gene therapy: review and perspective. Journal of Biomedical Science, 26(1), 1-12.
[17] Weinberg, M. S., & Morris, K. V. (2016). Gene therapy: the science, the technology, and the challenges. Dialogues in Clinical Neuroscience, 18(4), 323-332.
[18] Ginn, S. L., Amaya, A. K., & Alexander, I. E. (2018). Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine, 20(5), e3015.
[19] Bainbridge, J. W., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., ... & Ali, R. R. (2015). Long-term effect of gene therapy on Leber's congenital amaurosis. New England Journal of Medicine, 372(20), 1887-1897.
[20] Porteus, M. (2019). A new class of medicines through DNA editing. New England Journal of Medicine, 380(10), 947-959.
[21] Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., ... & Zhang, X. (2020). First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discovery, 10(2), 172-183.
[22] June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.
[23] Ginn, S. L., Amaya, A. K., & Alexander, I. E. (2018). Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine, 20(5), e3015.
[24] Sadelain, M., Rivière, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423-431.
[25] Wang, D., Li, W., & Lu, Y. (2018). Gene therapy for HIV/AIDS. Frontiers in Immunology, 9, 2828.
[26] Simonato, M., Bennett, J., Boulis, N. M., Castro, M. G., Fink, D. J., Goins, W. F., ... & Glorioso, J. C. (2013). Progress in gene therapy for neurological disorders. Nature Reviews Neurology, 9(5), 277-291.
[27] Hajjar, R. J., & Isele, R. R. (2019). Gene therapy for the treatment of heart failure: Promise postponed. European Heart Journal, 40(27), 2158-2160.
[28] Ginn, S. L., & Alexander, I. E. (2013). Gene therapy for inherited diseases. The Medical Journal of Australia, 199(5), 310-314.

